TY - JOUR
T1 - Enhancement of the T cell response to a mycobacterial peptide by conjugation to synthetic branched polypeptide
AU - Wilkinson, Katalin A.
AU - Hudecz, Ferenc
AU - Martin Vordermeier, H.
AU - Ivanyi, Juraj
AU - J.wilkinson, Robert
PY - 1999/9/1
Y1 - 1999/9/1
N2 - A peptide-based approach towards improving the immunodiagnosis of, and vaccination against, tuberculosis faces the problems of MHC restriction of T cell recognition and the poor immunogenicity of peptides in the absence of adjuvant. We sought to compensate this by the use of synthetic branched polypeptides of the poly[Lys-(X(i)-DL-Ala(m))] type, containing a glutamic acid residue (EAK), and further modified either by succinylation (SucEAK) or acetylation (AcEAK). These carriers were conjugated to two permissively recognized peptides of Mycobacterium tuberculosis. The 38p350-369-SucEAK conjugate enhanced IFN-γ production more than 13-fold (from 22.6 to 294 pg/ml, p = 0.001) in peripheral blood mononuclear cells from healthy subjects, and 8.7-fold (p = 0.012) in cells from tuberculosis patients. The effect was dependent on the carrier used and on covalent linkage of SucEAK to 38p350-369. An increased response occurred best in cells from subjects bearing at least one HLA-DR allele for which 38p350-369 had high binding affinity and required cellular processing of the conjugate as inhibitors (chloroquine and wortmannin) blocked the IFN-γ response. SucEAK conjugation of peptide 16p91-110 did not significantly increase IFN-γ production, indicating that the ability of conjugation to enhance the response was peptide structure dependent. These data indicate that the use of SucEAK polymer coupled with permissively recognized peptides could contribute to the development of an improved immunodiagnostic or vaccine reagent for tuberculosis.
AB - A peptide-based approach towards improving the immunodiagnosis of, and vaccination against, tuberculosis faces the problems of MHC restriction of T cell recognition and the poor immunogenicity of peptides in the absence of adjuvant. We sought to compensate this by the use of synthetic branched polypeptides of the poly[Lys-(X(i)-DL-Ala(m))] type, containing a glutamic acid residue (EAK), and further modified either by succinylation (SucEAK) or acetylation (AcEAK). These carriers were conjugated to two permissively recognized peptides of Mycobacterium tuberculosis. The 38p350-369-SucEAK conjugate enhanced IFN-γ production more than 13-fold (from 22.6 to 294 pg/ml, p = 0.001) in peripheral blood mononuclear cells from healthy subjects, and 8.7-fold (p = 0.012) in cells from tuberculosis patients. The effect was dependent on the carrier used and on covalent linkage of SucEAK to 38p350-369. An increased response occurred best in cells from subjects bearing at least one HLA-DR allele for which 38p350-369 had high binding affinity and required cellular processing of the conjugate as inhibitors (chloroquine and wortmannin) blocked the IFN-γ response. SucEAK conjugation of peptide 16p91-110 did not significantly increase IFN-γ production, indicating that the ability of conjugation to enhance the response was peptide structure dependent. These data indicate that the use of SucEAK polymer coupled with permissively recognized peptides could contribute to the development of an improved immunodiagnostic or vaccine reagent for tuberculosis.
KW - 38-kDa antigen
KW - Epitope
KW - Peptide
KW - T lymphocyte
KW - Tuberculosis
KW - α-crystallin
KW - Amino Acid Sequence
KW - Bacterial Proteins/immunology
KW - Dose-Response Relationship, Immunologic
KW - Mycobacterium tuberculosis/immunology
KW - Humans
KW - Intercellular Signaling Peptides and Proteins
KW - Molecular Sequence Data
KW - Male
KW - Alleles
KW - Adult
KW - Female
KW - Peptides/immunology
KW - T-Lymphocytes/drug effects
KW - Vaccines, Synthetic/immunology
KW - Immunoconjugates/metabolism
UR - http://www.scopus.com/inward/record.url?scp=0033400776&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1521-4141(199909)29:09<2788::AID-IMMU2788>3.0.CO;2-4
DO - 10.1002/(SICI)1521-4141(199909)29:09<2788::AID-IMMU2788>3.0.CO;2-4
M3 - Article
C2 - 10508253
AN - SCOPUS:0033400776
SN - 0014-2980
VL - 29
SP - 2788
EP - 2796
JO - European Journal of Immunology
JF - European Journal of Immunology
IS - 9
ER -